Marc Macaluso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marc Macaluso has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Padmanee Sharma
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
66 shared publications - Sonali Jindal
James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, USA
66 shared publications - Sreyashi Basu
James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, USA
66 shared publications - Aidi Gu
Immunotherapy Platform, University of MD Anderson Cancer Center, Houston, Texas. 7
38 shared publications - Amishi Yogesh Shah
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
38 shared publications - Aradhana M. Venkatesan
Department of Abdominal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex
38 shared publications
Latest Publications
- Open Access
Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
Open AccessMacrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Table S2. Gene expression of PVSCs.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Table S2. Gene expression of PVSCs.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Fig. S7 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S7. Manual annotation of regions of interest with and without MVP and areas with normal perivascular morphology adjacent to areas of MVP.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S7 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S7. Manual annotation of regions of interest with and without MVP and areas with normal perivascular morphology adjacent to areas of MVP.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Fig. S6 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S6. Multiplex immunofluorescence of additional PVSC and endothelial cell markers. a. TAGLN and DCN, were expressed to a similar degree (45.07% ± 24.0% and 28.91% ± 21.6%; p = 0.24) in PDGFRβ+ cells, but CD34, an endothelial cell marker, was minimally expressed (1.37% ± 0.69%; p = 0.002, Mann-Whitney U test). b. Graphical representation of co-localization data in (A). Red datapoints represent glioma cases with MVP, while black datapoints represent glioma cases without MVP.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S6 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S6. Multiplex immunofluorescence of additional PVSC and endothelial cell markers. a. TAGLN and DCN, were expressed to a similar degree (45.07% ± 24.0% and 28.91% ± 21.6%; p = 0.24) in PDGFRβ+ cells, but CD34, an endothelial cell marker, was minimally expressed (1.37% ± 0.69%; p = 0.002, Mann-Whitney U test). b. Graphical representation of co-localization data in (A). Red datapoints represent glioma cases with MVP, while black datapoints represent glioma cases without MVP.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Fig. S15 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S15. Expression of immune checkpoint inhibitors.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S15 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S15. Expression of immune checkpoint inhibitors.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Fig. S20 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S20. Correlation of the COL3A1, PCOLCE, TIMP1, NNMT, and COL1A1 signature with survival in GBM. a. The gene signature showed no difference in disease-free survival in the TCGA-glioblastoma cohort (p = 0.22). b. The gene signature showed no difference in overall survival in the TCGA-glioblastoma cohort (p = 0.42). c. The gene signature showed a difference in disease-free survival in the more recent Cloughesy and colleagues GBM cohort (p = 0.045). d. The gene signature nearly showed a difference in overall survival in the more recent Cloughesy and colleagues GBM cohort (p = 0.052).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S20 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S20. Correlation of the COL3A1, PCOLCE, TIMP1, NNMT, and COL1A1 signature with survival in GBM. a. The gene signature showed no difference in disease-free survival in the TCGA-glioblastoma cohort (p = 0.22). b. The gene signature showed no difference in overall survival in the TCGA-glioblastoma cohort (p = 0.42). c. The gene signature showed a difference in disease-free survival in the more recent Cloughesy and colleagues GBM cohort (p = 0.045). d. The gene signature nearly showed a difference in overall survival in the more recent Cloughesy and colleagues GBM cohort (p = 0.052).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Microvascular proliferation (MVP) is a disease-defining hallmark of glioblastoma and other World Health Organization grade 4 gliomas. MVP also serves as a poor prognostic marker in various solid tumors. Despite its clinical significance, the mechanisms and biological consequences of MVP are controversial and remain unclear. In this study, we performed single-cell RNA sequencing on paired CD45−CD105+ vascular/perivascular stromal cells (PVSC) and CD45+CD105± immune cells from 16 primary glioma patient samples, both with and without MVP. This analysis revealed the presence of developmentally related mesenchymal stem cells alongside cancer-associated fibroblasts, pericytes, fibromyocytes, and smooth muscle cells within the CD45−CD105+ compartment. RNA velocity analysis identified PDGFRB as a putative driver gene guiding mesenchymal stem cells toward more mature PVSCs in the context of MVP. Signaling network analysis and digital spatial profiling uncovered interactions between PDGFRB+ PVSCs and immunosuppressive myeloid cell subsets enriched in the perivascular niche, suggesting targetable receptor–ligand interactions. Additionally, a gene signature of MVP-associated PVSCs from gliomas predicted worse prognosis in multiple other solid tumors. This study provides a transcriptomic cell atlas of PVSCs and immune cells in glioma, helping to refine the biological model of MVP which has traditionally focused on endothelial cells.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Microvascular proliferation (MVP) is a disease-defining hallmark of glioblastoma and other World Health Organization grade 4 gliomas. MVP also serves as a poor prognostic marker in various solid tumors. Despite its clinical significance, the mechanisms and biological consequences of MVP are controversial and remain unclear. In this study, we performed single-cell RNA sequencing on paired CD45−CD105+ vascular/perivascular stromal cells (PVSC) and CD45+CD105± immune cells from 16 primary glioma patient samples, both with and without MVP. This analysis revealed the presence of developmentally related mesenchymal stem cells alongside cancer-associated fibroblasts, pericytes, fibromyocytes, and smooth muscle cells within the CD45−CD105+ compartment. RNA velocity analysis identified PDGFRB as a putative driver gene guiding mesenchymal stem cells toward more mature PVSCs in the context of MVP. Signaling network analysis and digital spatial profiling uncovered interactions between PDGFRB+ PVSCs and immunosuppressive myeloid cell subsets enriched in the perivascular niche, suggesting targetable receptor–ligand interactions. Additionally, a gene signature of MVP-associated PVSCs from gliomas predicted worse prognosis in multiple other solid tumors. This study provides a transcriptomic cell atlas of PVSCs and immune cells in glioma, helping to refine the biological model of MVP which has traditionally focused on endothelial cells.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Fig. S16 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S16. Corroborating immune markers from the digital spatial profiling panel with the scRNA-seq dataset.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S16 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S16. Corroborating immune markers from the digital spatial profiling panel with the scRNA-seq dataset.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Fig. S1 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S1. Representative example of gating strategy for fluorescence-activated cell sorting of CD45+ and CD45-CD105+ cells.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S1 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S1. Representative example of gating strategy for fluorescence-activated cell sorting of CD45+ and CD45-CD105+ cells.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Fig. S2 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S2. Violin plots of genes used to annotate MSCs, fibroblastic cells, and pericytes.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S2 from Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome
Fig. S2. Violin plots of genes used to annotate MSCs, fibroblastic cells, and pericytes.